Eastman Chemical Company

▲ Bull Case

• ◆Molecular recycling validates and re-rates the stock: Kingsport hits 85-90% utilization at premium pricing by FY2027, contributing $150-200M+ incremental EBITDA. France facility receives EU subsidy commitment. Multiple expands from ~8x to 11x EV/EBITDA as circular-economy moat is validated. Implied $190–$210 stock; ~150-185% total return over 24 months.
• ◆AFP volume recovery + Advanced Materials specialty mix: Tritan medical/auto penetration converts pipeline to revenue (+$150M at 30% margin); AFP destocking is structurally complete by FY2027; Advanced Materials EBITDA margins expand to 26-28% from the molecular-recycling premium and Tritan high-value mix.
• ◆Fibers durability + capital return: Fibers EBITDA holds $475M+ through FY2028 (international markets offset US menthol ban impact); leverage normalizes to <2.0x, restarting aggressive buybacks at depressed prices; the 30-year dividend growth streak extends, supporting income-investor base.

▼ Bear Case

• ◆Molecular recycling stalls: Kingsport stuck at 50-60% utilization; unit economics show sub-10% ROIC; ~$1B investment becomes a capital-allocation drag rather than a growth engine. Stock de-rates to 6-7x EV/EBITDA. Implied $50–$65 stock.
• ◆Fibers acceleration + cyclical second leg: FDA menthol ban implementation hits FY2026; heat-not-burn substitution accelerates; Fibers EBITDA falls to $300–350M by FY2028 (vs. $450M base); combined with industrial recession, leverage spikes above 3.5x and credit ratings come under pressure; dividend growth pauses for first time in 30+ years.
• ◆Margin step-up doesn't materialize: The FY2026→FY2027 EBITDA margin expansion of ~600bp is the model's most aggressive assumption. If volume re-leveraging is less than modeled, FY2027 EBITDA stays near $1.9B instead of $2.4B; fair value compresses to $80–90 (vs. $140 base).

“Sell-side analysts are anchored on visible FY2026 earnings power (consensus $5.75 EPS) and applying a modest re-rating to a $84 average price target — essentially a pay-for-what-you-can-see stance. The Buy rating is consensus but not high-conviction; analysts are reluctant to extrapolate the FY2027 EBITDA step-up because Q1 2026 came in below expectations. The variant view is that the market is mis-pricing two distinct things: (1) the optionality of molecular recycling at a structurally non-commodity moat, and (2) the durability of Fibers cash flow during the investment phase. The most contested question: Is molecular recycling a value-creating specialty business or commodity-economics greenwash? Eastman is the only large-cap specialty chemical company with a commercial-scale molecular recycling facility in steady-state operation — that data point gets resolved over the next 4-8 quarters.”

• ◆Q3/Q4 2026 earnings — molecular recycling revenue disclosure. Run-rate above $100M quarterly = strong validation; below $75M = bear-case confirmation.
• ◆AFP segment volume trajectory through FY2026 — whether destocking second leg ends or persists.
• ◆FY2026 guidance vs. consensus — conservative-guide-then-raise pattern is positive; guidance cut would be major negative.
• ◆Leverage trajectory — net leverage moving below 2.5x supports re-rating; staying above 3x maintains the discount.
• ◆France PRT facility approval — €800M–1B project pending EU subsidy. Approval = +$10–15 stock.
• ◆Tritan medical/auto OEM qualifications — each new major qualification = $50–150M revenue over 3-5 years.
• ◆500,000 MT molecular recycling capacity target — management's 2030 goal; if achieved, transforms valuation framing entirely.

• ◆Molecular recycling execution failure (Probability MEDIUM / Impact SEVERE) — Kingsport stuck at sub-economic utilization; $1B investment generates sub-WACC returns; stock de-rates 15-25%.
• ◆Accelerated Fibers decline (Probability HIGH / Impact HIGH) — FDA menthol ban + heat-not-burn substitution + Chinese capacity additions could cut Fibers EBITDA by 30-40% over 5 years.
• ◆Destocking recurrence / cyclical second leg (Probability MEDIUM-HIGH / Impact MEDIUM-HIGH) — Q1 2026 actuals (rev −5% YoY) are early evidence; if FY2026 fails to show recovery in H2, the EBITDA margin step-up to FY2027 is invalidated.
• ◆European industrial recession + currency — Saflex demand and EMEA additives ~28-30% of revenue; each 5% USD strengthening = $130–150M revenue headwind.
• ◆WACC expansion if rates stay higher for longer — each 100bps WACC = ~$20/share IV reduction.
• ◆China specialty polymer competition — SK ECOTRIA, novel BPA-free alternatives erode Tritan pricing premium over 3-5 years.
• ◆Goodwill impairment continuation — Taminco-related Additives goodwill ($1.5B+ exposure); further impairments possible if AFP margins stay depressed.